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http://dx.doi.org/10.1016/j.bbmt.20INTRODUCTION underwent transplantation early in the course of the disease,
Systemic light chain amyloidosis (LCA) is a raremonoclonal
B cell disorder characterized by the accumulation ofmisfolded
monoclonal light chain fragments within the heart, kidney,
liver, gut, peripheral nerves, and other tissues, resulting in
damage to these organs. Median survival is poor (less than
3 years in many series) and most closely associated with the
degree of cardiac involvement [1-5]. However, recent progress
in the diagnosis, characterization, and management of pa-
tients with LCA necessitates thoughtful reassessment of the
role of high-dose chemotherapy in the management of this
challenging disease. For years, the pace of improvement has
been hampered to some degree by the rarity of the condition,
lack of good preclinical models, heterogeneity in clinical pre-
sentation, and less than enthusiastic support from pharma-
ceutical companies and national organizations. Accrual to
prospective clinical trials, critically important to evaluate
several of the newer treatment approaches, has often been
sluggish at many centers or trials have not been available.
Thus, high-dose chemotherapy and autologous hematopoietic
cell transplantation (HCT) continues to be considered a suit-
able frontline therapy for appropriate LCA patients.
The role of high-dose melphalan and HCT in LCA was
initially explored in the early 1990s [6]. Although treatment-
related mortality (TRM) was frighteningly high (>30%) in
these early experiences, long-term survivors enjoying good
quality of life were observed and, eventually, this treatment
became an established part of the amyloidosis therapeutic
armamentarium more than a decade ago [1,7,8]. Notwith-
standing, the only prospective randomized trial completed to
date comparing high-dose therapy to conventional chemo-
therapy failed to demonstrate a beneﬁt for LCA patients whox.doi.org/10.1016/j.bbmt.2013.11.015.
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13.11.035and even suggested they may do worse, with median overall
survival of 22.2 months in the high-dose chemotherapy
group and 56.9 months in the group treated conventionally
(P ¼ .04) [9]. The trial results were reported in 2007 and fell
under heavy criticism because of the extremely high rate of
TRM in the group who underwent transplantation (24%) and
the inclusion of patients who underwent transplantation at
centers with little to no experience using high-dose
chemotherapy in patients with LCA [10]. Nevertheless, a
landmark analysis with long-term follow-up failed to
demonstrate an advantage to high-dose chemotherapy, even
in those patients surviving the ﬁrst 100 days of HCT [10].
Further, a subsequent meta-analysis, also heavily criticized,
again failed to demonstrate a beneﬁt to HCT [11,12]. With the
advent of immunomodulatory drugs and proteasome in-
hibitors, hematological response rates and organ function
improvements have increased and demand that we question
the value of high-dose chemotherapy and HCT, even in less
risky patients with LCA, given the availability of effective and
potentially less toxic therapies [5,13].
The greatest number of autologous HCT for patients with
LCA are performed within the United States [14]. Notwith-
standing, the US National Comprehensive Cancer Network
2013 guidelines for treatment of systemic LCA do not make
ﬁrm recommendations for ﬁrst line therapy and instead
include high-dose chemotherapy as 1 of a number of ther-
apeutic considerations for the management of these pa-
tients (all recommendations being category 2a) [15]. They
conclude that “the optimal therapy for systemic LCA still
remains unknown, the National Comprehensive Cancer
Network panel members strongly encourage treatment in
the context of a clinical trial when possible.” Unfortunately,
most patients are either ineligible for or not offered clinical
trials [5,13,16]. So, which patients are appropriate candi-
dates for HCT outside the context of a clinical trial? Should
these patients undergo transplantation only at specialized
centers with signiﬁcant experience providing trans-
plantations for patients with LCA, or is it appropriate for
them to undergo HCT at centers that perform fewer than 5erican Society for Blood and Marrow Transplantation.
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stringent guidelines established for selecting appropriate
candidates, and should each center performing such
transplantations follow established guidelines for all as-
pects of supportive care, including stem cell mobilization
and procurement, chemotherapy administration, and post-
transplantation management? We will address some of
these questions here.
Many within the amyloidosis treatment community have
questioned the value of high-dose chemotherapy, given the
high risk of TRM and in light of the results of the only ran-
domized study [5,13,17]. As mentioned, the French prospec-
tive study was believed to be highly ﬂawed by several
members of the blood and marrow transplantation commu-
nity, whomay themselves be biased toward the value of high-
dose chemotherapy [9,10]. Appropriately, issues were raised
about patient selection; the inclusion of high-risk patients
with cardiac involvement, who in retrospect should probably
have been excluded; the lack of inclusion of biomarkers to
predict prognosis; the lack of experience at many of the
participating centers; the dose of melphalan used; and the
protracted length of time required to complete the study.
Many have pointed toward these criticisms to downplay the
signiﬁcance of the study results. In rebuttal, the study authors
performed a follow-up landmark analysis that accounted for
patients who died early after transplantation [10]. This anal-
ysis still failed to show an advantage for patients who had
received high-dose melphalan, once again questioning the
overall value of melphalan dose escalation. On the positive
side, the ﬁndings forced the transplantation community to
reconsider the salient issues and tobetter establish guidelines
for patient eligibility and supportive care. This has resulted in
substantial improvements in the risk of TRM in recent years
[18-21]. Thus, it is reasonable to re-examine the critical
questions thateachcentermust considerwhenevaluating the
role of high-dose chemotherapy in the treatment of their
patients with LCA. Much of the current decision making re-
quires a clear understanding of the goals of therapy, a
comprehensive assessment of the extent of disease in any 1
individual, and based on that, the overall prognosis and de-
gree of risk of morbidity and mortality related to the primary
therapy chosen [13,17-19,21-24]. An extensive discussion of
the pathophysiology of LCA, as well as its diagnosis and
management, is beyond the scope of this review, but the
reader is referred to several excellent recent reviews covering
these topics [3-5,7,13,16,25-32].
WHAT ARE THE PRIMARY GOALS OF THERAPY
IN THIS DISEASE?
Systemic therapy designed to destroy the plasma cell
clones responsible for the synthesis of immunoglobulin light
chain remains the primary approach [1,7,13,20,21,29,33-40].
The goal is to promptly eradicate the misfolded amyloid light
chains, resulting in improvement in the function of the
involved organ(s). The importance of a good hematological
response has beenwell established over the last several years
[13,38]. Hematological response (HR) is considered essential
for the establishment of an organ response, although HR does
not always translate into organ improvement. Consensus
criteria have been developed for the assessment of HR and
organ response [37]. The inclusion of the serum-free light
chain assay has greatly improved the assessment of HR, as has
the use of cardiac biomarkers such as cardiac troponin and
NT-proBNP [41,42]. As is the case with multiple myeloma,
there is some controversy as to whether a complete HR isnecessary for long-term clinical beneﬁt, particularly if organ
response is observed and organ dysfunction is stabilized or
improved [5,13,16,38,40,43]. Notwithstanding, long-term re-
sponses have been seen, particularly in patients achieving a
complete response to high-dose chemotherapy [43]. In
addition to depth of response, the rapidity of response is also
an important factor inﬂuencing the likelihood of achieving
organ stabilization or improvement.
Achievement of a rapid HR certainly pertains to patients
receiving high-dose chemotherapy, but it is also relevant
when one considers nontransplantation therapies and the
decision to use a regimen containing immunomodulatory
agents (eg, thalidomide, lenalidomide, or pomalidomide)
versus a proteasome inhibitor (bortezomib, carﬁlzomib)
[5,13,16,18,44-55]. Data suggest HR and even organ responses
may be observedmore rapidlywith regimens incorporating a
proteosome inhibitor [5,49,50]. The addition of bortezomib
may improve the rapidity of response and is currently being
studied in a randomized prospective trial comparing borte-
zomib added to standard melphalan and dexamethasone
[46,51,56,57]. Whether the addition of cyclophosphamide to
bortezomib and dexamethasone improves the depth and
rapidity of response remains an open question, but many of
the best responses have been seenwith the so-called CyBorD
(cyclophosphamide, bortezomib, and dexamethasone)
regimen [49,51]. As with multiple myeloma, numerous com-
binations of novel agents are currently being evaluated in
patients who are not considered candidates for HCT, but may
also prove effective in patients traditionally considered for
high dose chemotherapy as primary treatment.
Older studies failed to establish the beneﬁt of induction
chemotherapy before high-dose chemotherapy and HCT in
LCA, but given the availability of potentially better induction
regimens that work rapidly, the value of both induction and
consolidation chemotherapy in the context of high-dose
chemotherapy is being revisited in ongoing clinical trials
[7,16,58,59]. Most would agree that depth of response in-
ﬂuences the potential for prolonged survival and should also
translate into an improved quality of life. This remains to be
establishedprospectively. For thosewhowouldadvocatehigh-
dose chemotherapy, depth of response is the critical factor in
establishing an overall beneﬁt in these patients [16,43].
WHAT ROLE HAS PATIENT SELECTION PLAYED IN THE
FAVORABLE OUTCOMES OBSERVED AFTER HCT?
Patient selection exerts a profound inﬂuence on treat-
ment outcome in virtually any clinical trial setting. Given the
very high rates of TRM (particularly within 100 days of
transplantation) reported in the early trials, which estab-
lished a role for high-dose melphalan in the treatment of
LCA, it is hard to imagine that the pioneering centers were
“cherry picking” the best patients [6,58-61]. Much was
learned through these preliminary explorations of high-dose
chemotherapy. Early on, and not surprisingly, it became clear
that the number and extent of organ involvement, patient
age, performance status, and, in particular, the severity of
cardiac involvement exerted a heavy inﬂuence on the risk
of TRM [6,58-61]. Retrospective analyses demonstrated
that many of the early deaths were in patients with the
most severe cardiac involvement and established the basic
tenet that patients with very advanced cardiac involvement
should probably not undergo high-dose chemotherapy
[1,2,11,20,21,29]. However, even that statement has been
questioned by recent data from theMayo Clinic [7,29,47]. The
establishment of the Mayo staging system has provided a
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teristics across centers [24]. The use of cardiac biomarkers
(troponin, NT-proBNP) before HCT has provided the most
objective criteria for both patient stratiﬁcation as well as
inclusion and/or exclusion from high-dose chemotherapy. A
recent report fromMayo Clinic established that patients with
NT-proBNP levels greater than 5000 pg/mL should not un-
dergo HCT given their extremely high risk of TRM [47]. The
use of serum biomarkers provides a more objective means to
predict a patient’s risk and to compare results across studies
rather than number of organs involved, given the potential
variability in assessing organ involvement from center to
center. Beyond risk of TRM, recent data also suggest that the
extent of bone marrow plasma cell involvement heavily in-
ﬂuences the likelihood of long-term survival, and patients
with greater than 10%marrow plasma cell involvement seem
to have worse overall survival [62-64].
The issue of TRM (as high as 30% in some series) becomes
even more important now that there are other potentially
effective therapies available to these patients [5,7,13]. So,what
shouldbeconsideredanacceptable rate of TRM, at leastwithin
the ﬁrst 100 days of transplantation? Clearly, rates above 10%
seem unacceptably high except for certain exceptional situa-
tions. It would seem reasonable that rates approaching those
observedwith other hematologicalmalignancies amenable to
autografting (<5%) should be the goal. However, if such
stringent criteria are used, the vast majority of patients are
unlikely to be candidates for HCT, even at the experienced
transplantation centers using well-established supportive
care guidelines. It hasbeenestimated thatnomore than20% to
30% of all patients diagnosed with primary LCA would be
eligible for upfront HCT if the goal is to maintain a low risk of
TRM [5,13,16]. From the perspective of this reviewer, the
availability of potentially effective conventional therapies
necessitates thatweaccept only a low risk of TRM.Given these
concerns, randomized prospective trials comparing HCT with
conventional regimens are even more urgently needed than
before, but they are unlikely to be performed. For instance, a
recent trial in the United Kingdom comparing cyclophospha-
mide, thalidomide, and dexamethasone to high-dose chemo-
therapywas closedbecause of lack of accrual [5].Whether this
was due to the lack of equipoise on this issue or othermatters
in unclear. In the United States, where themajority of upfront
transplantations are performed, there are currently no plans
for a prospective trial comparing high-dose to more conven-
tional chemotherapy. Unfortunately, this leaves both patients
and the physicians caring for them in a quandary over the best
initial approach. A conservativemanagement approachwould
be to embark initially on a less toxic, better tolerated con-
ventional regimen ﬁrst, to be followed by high-dose chemo-
therapy if certain response goals are not met. This approach
has recently been advocated by some, but it could be risky if a
patient thenmisses the opportunity to beneﬁt fromhigh-dose
chemotherapy [5]. In the absence of clinical trials, the Mayo
Clinic guidelines for selecting transplantation candidates
should be adopted bymost centers until better treatments are
available [47].
IF THE DECISION HAS BEEN MADE TO MOVE FORWARD
WITH HIGH-DOSE CHEMOTHERAPY, ARE THERE
ESTABLISHED “BEST PRACTICES” FOR THE
MANAGEMENT OF THESE PATIENTS? DOES CENTER
EXPERIENCE MATTER AND, IF SO, HOW MUCH?
Fortuitously, the centers with the greatest longitudinal
experience in providing transplantations to patients withLCA have developed and published guidelines tomitigate the
risk of morbidity and mortality throughout the process of
stem cell mobilization and procurement and after high-dose
chemotherapy [1,2,16,18,29,31,58]. At both the Mayo Clinic
and Boston University, TRM has markedly improved over the
last several years, based on experience in supporting these
patients, as well as on the establishment of better selection
criteria [2,43,47]. Typically these go hand in hand. Centers
performing fewer than 5 to 10 transplantations annually for
amyloidosis are well advised to follow guidelines established
by these larger programs. A recent review of registrations to
the Center for International Blood and Marrow Transplant
Research determined that the majority of centers in the
United States that perform transplantations in patients with
LCA do so in less than 5 patients annually (Marcelo Pasquini,
personal communication). At Ohio State University, where
we perform transplantations on no more than 5 LCA patients
annually (but perform 80 to 100 multiple myeloma auto-
grafts yearly), we have carefully reviewed the Mayo Clinic
and Boston University experiences, adopted many of their
practices, and have developed our own criteria for support-
ing patients through stem cell mobilization and procure-
ment, determining the dosage of melphalan, and the use of
blood product and growth factor support after peripheral
blood cell stem cell transplantation (PBCT). The outcomes for
these patients are continuously reviewed at our site, and
guidelines are revised according to outcomes, based on a
process of continuous quality improvement. Based on a
combination of strict selection criteria and stringent sup-
portive care guidelines, only 1 of 29 LCA patients undergoing
PBCT at our center has experienced TRM before day 100
(Yvonne Efebera, unpublished observation).
HOW SHOULD WE MOBILIZE STEM CELLS?
Akin to patients with multiple myeloma, most patients
treated in the early days of transplantation for LCA under-
went stem cell mobilization following high-dose cyclo-
phosphamide [1,6,9,11,60,61,65,66]. Unfortunately, many
patients did not tolerate this approach nearly as well as their
myeloma counterparts, primarily because of a high risk of
mortality, secondary to cardiac events, infection, or bleeding
episodes. Alternative strategies were sought and a shift
towards cytokine-based mobilization using granulocyte
colonyestimulating factor (G-CSF) appears to have substan-
tially lowered substantially the risk of morbidity and mor-
tality during stem cell mobilization [1,2,21,58]. G-CSFebased
mobilization has become the standard method by which
hematopoietic-reconstituting cells are obtained from LCA
patients. Meticulous attention to volume shifts and other
apheresis techniques are critical, as well, as many of these
patients have suffered severe complications during the pro-
cess of leukapheresis. Given that most of these patients have
not received prior chemotherapy or, if they have, it has been
of limited duration, G-CSF should be adequate to mobilize a
sufﬁcient stem cell dose in themajority of these patients. The
presence of amyloid deposition within the bone marrow
does not appear to adversely affect stem cell mobilization
[67]. Plerixafor has been added to G-CSF in a small number of
LCA patients, and its use appears to be safe [68]. However,
plerixafor administration should probably be reserved for
patients failing to mobilize adequately with G-CSF alone.
Because the use of tandem transplantation has not been
established in patients with LCA, sufﬁcient hematopoietic
progenitor cells to support 1 course of high-dose chemo-
therapy is generally adequate [58,66]. However, given
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post transplantation, it may be wise to procure at least 4 to
5  106 CD34þ cells/kg in these patients to promote prompt
neutrophil recovery in the absence of G-CSF use after HCT.
The optimal CD34 dose for infusion following high-dose
melphalan in LCA patients has not been well established.
WHAT IS THE APPROPRIATE MELPHALAN DOSE AND
SHOULD THAT DOSE BE PATIENT SPECIFIC?
The prospective French randomized trial used melphalan
200 mg/m2 as the standard dose, with reduction to 140 mg/
m2 for older patients and for those with poor cardiac or renal
function [9]. Others have advocated for adjustments in the
dose of high-dose melphalan, based on the presence or
absence of organ involvement and/or age, with doses ranging
from 100 mg/m2 to 200 mg/m2 reported in the published
studies [18-20,22]. Given that hematological response may
be related to dose received, there is a potential downside
with the use of doses reduced to levels lower than typically
used in multiple myeloma. This is once again controversial,
particularly now that the ultimate beneﬁt of high-dose
melphalan in LCA is being questioned. Further, the pharma-
cology of high-dose melphalan in patients with LCA has not
been well studied. In multiple myeloma patients, there are
data to suggest that pharmacogenomic factors may signiﬁ-
cantly inﬂuence exposure to high-dose melphalan [69]. At
Ohio State University, a pharmacogenomics study inmultiple
myeloma is ongoing. We hypothesize that there may be
important differences inmelphalan handling among patients
and that toxicity may be related either to peak concentra-
tions achieved or, alternatively, to area under the curve and
that, perhaps, melphalan may be better dosed based on
measured or predicted pharmacokinetics, similar to dosing
for busulfan. This may be even more important in LCA pa-
tients, given the high risk of TRM. In this high-risk group of
patients, it would be interesting to consider individualized
dosing of melphalan based not only on clinical characteristics
such as age, renal function, and cardiac reserve, but also
based on pharmacogenetics. The value of pursuing this
strategy further will ultimately rest with the issue of
whether any dose escalation of melphalan is warranted.
The role of other types of high-dose chemotherapy drugs
for conditioning, the addition of other drugs, such as borte-
zomib, to a melphalan-based conditioning regimen, and the
use of other approaches, such as total body irradiation, have
been reported mainly from single centers with varying de-
grees of success [46,58,59,70]. Total body irradiation seems
excessively toxic in these patients [70]. However, no ﬁrm
recommendations can be made and it seems that high-dose
melphalan alone should remain the baseline conditioning
regimen outside the context of a clinical trial.
IS THERE A ROLE FOR CONSOLIDATION AND
MAINTENANCE AFTER TRANSPLANTATION, AS THERE IS
FOR MULTIPLE MYELOMA?
Depth of response is associated with beneﬁt from high-
dose chemotherapy, and data from multiple myeloma pa-
tients suggest that depth of response can be improved with
both consolidation and maintenance treatment after auto-
graft. Thus, there are currently studies evaluating the use of
consolidation andmaintenance strategies in LCA patients not
achieving complete response after 1 course of high-dose
melphalan [5,16,46,71]. Clearly, issues related to tolerability
are paramount, but given the availability of immunomodu-
latory drugs and proteasome inhibitors that have beenrelatively well tolerated, the question is, indeed, relevant.
One study from Memorial Sloan Kettering suggested
consolidation with bortezomib was both feasible and effec-
tive in this setting [46]. Others have reached similar con-
clusions [16]. Outside the context of a clinical trial, the use of
maintenance treatment, particularly with a drug like lenali-
domide, which has been associated with a potentially higher
risk of secondary malignancies, should be considered on a
case-by-case basis and the pros and cons discussed in detail
with the patient [71,72]. There are insufﬁcient data at present
to make any ﬁrm recommendations regarding maintenance
treatment in LCA after high-dose chemotherapy.
HOW MUCH GUIDANCE CAN WE EXPECT FROM
ONGOING CLINICAL TRIALS?
It seems as if most manuscripts published on the topic of
treatment of systemic LCA incorporate the conclusion that
prospective clinical trials are urgently needed. It is certainly
difﬁcult to argue with this conclusion, but what is the evi-
dence that sufﬁcient clinical trials are available or that they are
relevant to the majority of patients diagnosed with LCA? A
recent review of the Clinicaltrials.gov database (performed on
September 22, 2013), searching for either phase II or III trials
involving patients with systemic LCA, revealed a total of 8
phase II and 2 phase III studies. The pace of progress in this
disease may remain slow as a result, particularly given the
current NIH funding climate. Unfortunately, a number of
prospective trials have had to close because of poor accrual.
Whether this is due to study design issues, feasibility, lack of
relevance for themajority of LCA patients seen in practice, the
advancednature of disease inmany newlydiagnosed patients,
lack of publicity, or other factors is unclear. However, the
dearth of available trials represents a signiﬁcant impediment
toward further progress in the treatment of this very difﬁcult
disease. At a minimum, reports of experience with high-dose
therapy should include results not only for the patients who
hadunderwent transplantation, but also for those inwhoman
unsuccessful effort was made to procure cells that could be
used for transplantation. The prospective French study
accounted for both groups, but many retrospective reports
have included results only for patients who underwent
transplantation and did not account for the complications
associated with unsuccessful stem cell mobilization [9].
PUTTING IT ALL INTO CONTEXT: WHAT IS THE ROLE OF
HIGH-DOSE CHEMOTHERAPY IN 2014?
The role of high-dose chemotherapy remains unclear,
particularly for thosepatientswithLCAwhomaybedeemedto
be at anything more than a low risk for mortality related to
high-dose melphalan. It is difﬁcult to discount the fact that
many LCA patients have enjoyed prolonged progression-free
survival with good quality of life after high-dose chemo-
therapy and autologousHCT [13,16,43]. Clearly, themajority of
patients newly diagnosed with LCA are not candidates for
high-dose chemotherapy. Among the estimated 20% to 30% of
patients who have a low enough risk of TRM to be considered
for this procedure, who are best treated with this approach?
Patients should be placed on prospective clinical trials when-
ever possible. Patients with newly diagnosed LCA should be
considered for referral to centers focusing on this disease.
When that is not possible, patients should be referred to and
placed on LCA-speciﬁc clinical trials approved at local/regional
NCI-designated cancer centers within the United States,
whenever possible. A clinical trial, whether evaluating con-
ventional or high-dose chemotherapy as a strategy, would be
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clinical trial. Clearly not everyone would agree, and unfortu-
nately, the reality is that themajorityof LCApatientswill either
not be offered a clinical trial or will not be eligible. For those
whowould be eligible for a clinical trial but cannot participate
or choose not to participate, high-dose chemotherapy should
be offered to those patients willing to accept up to 5% to 10%
risk of TRM within the ﬁrst 100 days after transplantation.
Such patients should bedeemedﬁt andgood candidates based
on criteria established at the large referral centers. Preferably,
patients would undergo transplantation at centers that per-
form5 to 10 ormore transplantations for this disease annually,
although this is admittedly an arbitrary number. Each center
willing to offer HCT to a patient with LCA should, if they have
not already, adopt well-established criteria for transplantation
candidacy and should strongly consider the development of
LCA-speciﬁc supportive care guidelines within their center for
every aspect of the procedure, from stem cell mobilization to
supportive care, within the ﬁrst 3 to 4 months after HCT.
The United States’ blood and marrow transplantation
community should consider clarifying the role of PBCT in LCA.
The feasibility of a prospective trial supported by the US gov-
ernment, perhaps by the NIH-funded Blood and Marrow
Transplant Clinical Trials Network, should be seriously
considered. Unfortunately, given the rarity of this disorder and
heterogeneity of the patients at diagnosis, together with the
low proportion of patients eligible, such a study may not be
feasible, particularly if overall survival were chosen as the pri-
mary endpoint. Short of that, consistent registration of LCA
patients undergoing transplantation at centers within the
Center for InternationalBloodandMarrowTransplantResearch
should be mandatory, and outcomes at individual centers
should be scrutinized closely, particularly because many cen-
ters perform fewer than 5 transplantation in these patients
annually (Marcelo Pasquini, personal communication). The use
of cardiacandotherbiomarkers to establishcandidacy forhigh-
dose chemotherapy should become the standard of care
throughout centers and establishment of newer biomarkers
and genetic signatures should continue to be pursued.
After more than 20 years of studying the role of high-dose
chemotherapy in LCA, much has been learned.We knowwho
should probably not undergo transplantation, and we know
that there is certainly a signiﬁcant fraction of patients who
derive long-term beneﬁt from this approach. Better precision
in the identiﬁcation of those LCA patients who derive long-
term beneﬁt from high-dose chemotherapy in preference
to less toxic therapies should be a major goal in the next
decade, as should continued improvement in supportive
care, such that LCA patients undergoing HCT do not suffer
rates of TRM substantially higher than their counterparts
with multiple myeloma.
With the advent of novel therapies, it remains unclear
whether high-dose chemotherapy will maintain an estab-
lished role in the planned upfront therapy of LCA or if its use
will be relegated to a treatment for patients who have failed
to respond to 1 or a number of more conventional and less
toxic therapies. This is conceivable, given the recent devel-
opment of novel therapies, including antibody treatments
and methods to absorb amyloid ﬁbrils, which hold promise
for the future [73-76].ACKNOWLEDGMENTS
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